| 0 (0%) | 09-27 09:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.68 | 1-year : | 1.96 |
| Resists | First : | 1.44 | Second : | 1.68 |
| Pivot price | 1.3  |
|||
| Supports | First : | 1.13 | Second : | 0.94 |
| MAs | MA(5) : | 1.27 |
MA(20) : | 1.25 |
| MA(100) : | 0.88 |
MA(250) : | 0.85 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 50.8 |
D(3) : | 53.9 |
| RSI | RSI(14): 57.4 |
|||
| 52-week | High : | 1.52 | Low : | 0.33 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ONCY ] has closed above bottom band by 44.0%. Bollinger Bands are 52.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.3 - 1.31 | 1.31 - 1.31 |
| Low: | 1.19 - 1.19 | 1.19 - 1.2 |
| Close: | 1.28 - 1.29 | 1.29 - 1.3 |
Sun, 21 Sep 2025
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Tue, 16 Sep 2025
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion - PR Newswire
Tue, 16 Sep 2025
33% Response Rate: Oncolytics' Cancer Drug Triples Standard Treatment Efficacy in Rare SCAC Cancer Trial - Stock Titan
Mon, 08 Sep 2025
2.5X Survival Improvement: Oncolytics' Pelareorep Drug Shows Breakthrough in Colorectal Cancer Treatment - Stock Titan
Wed, 27 Aug 2025
Here's Why We're Watching Oncolytics Biotech's (NASDAQ:ONCY) Cash Burn Situation - Yahoo Finance
Wed, 13 Aug 2025
New Analyst Forecast: $ONCY Given 'Buy' Rating | ONCY Stock News - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 101 (M) |
| Shares Float | 99 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 1.6 (%) |
| Shares Short | 2,330 (K) |
| Shares Short P.Month | 2,440 (K) |
| EPS | -0.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -74.6 % |
| Return on Equity (ttm) | -249.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -25 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -4.78 |
| PEG Ratio | 0 |
| Price to Book value | 21.5 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|